Guardant Health (NASDAQ:GH) Director Musa Tariq Sells 116 Shares

Guardant Health, Inc. (NASDAQ:GH) Director Musa Tariq sold 116 shares of the firm’s stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $175.00, for a total value of $20,300.00. Following the sale, the director directly owned 11,449 shares in the company, valued at approximately $2,003,575. This represents a 1.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Musa Tariq also recently made the following trade(s):

• On Monday, August 17th, Musa Tariq sold 116 shares of Guardant Health stock. The stock was sold at an average price of $156.45, for a total value of $18,148.20.
• On Monday, June 22nd, Musa Tariq sold 1,951 shares of Guardant Health stock. The stock was sold at an average price of $131.16, for a total value of $255,893.16.

Guardant Health Price Performance

GH stock opened at $183.10 on Friday. Guardant Health, Inc. has a 1-year low of $55.38 and a 1-year high of $183.51. The business has a 50 day simple moving average of $160.71 and a two-hundred day simple moving average of $127.10. The company has a market capitalization of $24.57 billion, a price-to-earnings ratio of -52.46 and a beta of 1.57.

Guardant Health (NASDAQ:GH) last released its earnings results on Thursday, July 30th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.34. The company had revenue of $334.98 million during the quarter, compared to analysts’ expectations of $314.23 million. During the same period last year, the firm posted ($0.44) EPS. Guardant Health’s quarterly revenue was up 44.3% compared to the same quarter last year. Sell-side analysts anticipate that Guardant Health, Inc. will post -2.98 EPS for the current fiscal year.

Institutional Investors Weigh In On Guardant Health

Hedge funds and other institutional investors have recently modified their holdings of the business. Revere Asset Management Inc bought a new position in Guardant Health in the 2nd quarter valued at $3,994,000. Sequoia Financial Advisors LLC bought a new position in shares of Guardant Health in the second quarter worth about $216,000. First Light Asset Management LLC grew its holdings in shares of Guardant Health by 57.5% in the second quarter. First Light Asset Management LLC now owns 441,586 shares of the company’s stock worth $66,251,000 after purchasing an additional 161,287 shares during the last quarter. Tidal Investments LLC increased its stake in Guardant Health by 43.7% in the 2nd quarter. Tidal Investments LLC now owns 24,593 shares of the company’s stock worth $3,690,000 after buying an additional 7,473 shares during the period. Finally, MCF Advisors LLC increased its stake in Guardant Health by 755.0% in the 2nd quarter. MCF Advisors LLC now owns 171 shares of the company’s stock worth $26,000 after buying an additional 151 shares during the period. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have recently commented on GH. Royal Bank Of Canada increased their target price on Guardant Health from $185.00 to $200.00 and gave the company an “outperform” rating in a research report on Friday, July 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Guardant Health in a research report on Friday, July 17th. Rothschild & Co Redburn assumed coverage on shares of Guardant Health in a research note on Tuesday, September 8th. They issued a “buy” rating and a $203.00 price objective for the company. TD Cowen restated a “buy” rating on shares of Guardant Health in a research report on Tuesday, August 25th. Finally, JPMorgan Chase & Co. increased their price target on shares of Guardant Health from $185.00 to $195.00 and gave the company an “overweight” rating in a report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Guardant Health has a consensus rating of “Moderate Buy” and a consensus target price of $188.12.

More Guardant Health News

Here are the key news stories impacting Guardant Health this week:

• Positive Sentiment: Guardant Health was described as nearing a technical buy point as its sales outlook improves, reinforcing expectations for continued growth in its precision-oncology testing business. Guardant Health Nears Buy Point As Sales Outlook Brightens
• Positive Sentiment: Recent quarterly performance remains a key catalyst: revenue increased 44.3% year over year to about $335 million and exceeded analyst expectations, while the adjusted loss of $0.42 per share was narrower than the anticipated $0.76 loss. The results support the bullish sales narrative. Testing and diagnostics services stocks Q2 results
• Positive Sentiment: Wall Street sentiment is broadly favorable. Twenty-four analysts rate the stock Buy, one rates it Strong Buy and one rates it Sell; the average price target is approximately $188.12, with targets as high as $200. Guardant Health analyst ratings
• Neutral Sentiment: A comparison article examining Guardant Health and Joint did not identify a major new operating catalyst for GH, leaving the investment case centered primarily on growth, valuation and execution. Guardant Health and Joint comparison
• Negative Sentiment: Several insiders reported sales executed around $175-$178 per share. Director Steve Krognes sold 6,674 shares worth about $1.17 million, CTO Darya Chudova sold 7,738 shares worth about $1.38 million, and Director Alex Azar II sold 826 shares worth about $145,000. These transactions reduce insider ownership and may encourage profit-taking, although some were made under pre-arranged Rule 10b5-1 plans. Guardant Health insider sales

Guardant Health Company Profile

Guardant Health, Inc (NASDAQ:GH) is a precision oncology company that develops blood-based diagnostic tests designed to help detect cancer, guide treatment decisions and monitor patients over time. Its liquid biopsy technologies analyze tumor-related signals in blood, reducing the need for tissue biopsies in certain clinical and research settings.

The company’s products include Guardant360 tests, which profile advanced cancers and can help identify potentially actionable genomic alterations; Guardant Reveal, which is used to assess residual disease and recurrence risk; and Guardant Shield, a blood-based screening test for colorectal cancer.